technologythatenhancesthe powerof our ownimmunesystem.
Welfare-Incentivized.
About us
ImmunoX is a Biotechnology start-up developing and applying immunotherapy solutions against cancer
CAR-Macrophage cells manipulation strategies against solid tumours
Harnessing the combined powers of science and medicine to improve and extend the life of patients with severe diagnoses.
CAR-Macrophage cells
are specially engineered to fight cancer
Chimeric antigen receptors (CARs) are designed to redirect the effector function of immune cells against tumor targets.
Expression of these receptors in macrophages refines tumor recognition and improves phagocytic capacity.
The CAR-M therapeutic approach uses the ability of macrophages to infiltrate solid tumors and travel through the hostile tumor microenvironment to access tumor cells, eliminate them and activate an adaptive response.
mission
ImmunoX's goal is to create a platform for the development of advanced therapies against cancer aiming for impact and accessibility through the most affordable solutions on the market.
TEAM
ImmunoX is composed of a group of physician-scientists with more than 35 years of experience applied to immunology research.
Full professor at one of the most prestigious academic and scientific institutions in the world, and ranked among the "2% most relevant scientists on the planet" by Stanford University, Vanderson Rocha has more than 30 years of experience in assisting patients and conducting research on Hematology, Hemotherapy, and Cell Therapy. Consultant Professor at Oxford University, UK, he currently leads ImmunoX scientific effort as Chief Medical and Scientific Officer.
Doctor in Immunology at the University of São Paulo (USP, Brasil) and at the University of Lyon (France). Postdoctoral researcher at the Institut Curie and at Sorbonne Université, both in Paris (France). Research group leader at the Hospital das Clínicas - Faculty of Medicine at USP and at the D'OR Institute of Research and Education in São Paulo. His main focus is on basic and translational research projects in onco-immunology, with emphasis on the role of myeloid immune cells in tumors.
Full professor at one of the most prestigious academic and scientific institutions in the world, and ranked among the "2% most relevant scientists on the planet" by Stanford University, Vanderson Rocha has more than 30 years of experience in assisting patients and conducting research on Hematology, Hemotherapy, and Cell Therapy. Consultant Professor at Oxford University, UK, he currently leads ImmunoX scientific effort as Chief Medical and Scientific Officer.
Doctor in Immunology at the University of São Paulo (USP, Brasil) and at the University of Lyon (France). Postdoctoral researcher at the Institut Curie and at Sorbonne Université, both in Paris (France). Research group leader at the Hospital das Clínicas - Faculty of Medicine at USP and at the D'OR Institute of Research and Education in São Paulo. His main focus is on basic and translational research projects in onco-immunology, with emphasis on the role of myeloid immune cells in tumors.
ImmunoX is partnering with Sthorm Group to address the financing and delivery of cancer research and treatment through ViralCure, a blockchain-based alt-funding project for R&D.
Visit Viralcure